City analysts understand the companies they cover better than anyone - so it can pay to take note of their trading recommendations. 'Buy', 'hold' and 'sell' ratings can be a useful signal when it comes to deciding whether to buy a shar...
|Type||Buy / Hold / Sell|
|Year End 30th Jun||Unit||2017||2018||2019||2020||2021||2022E||2023E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
|Leverage (ttm)||Total||- Intang||+ Pension|
|Cash / Assets|
Latest News & Insights for CLIN
Broker recommendations can be a useful early clue in the hunt for stocks to add to your portfolio. These city analysts know the companies they cover better than most, so their views on whether to buy or sell them are worth considering....
The Clinigen (LON:CLIN) share price has risen by 5.63% over the past month and it’s currently trading at 637.5p. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue...
Broker research is an important consideration in the strategies of many investors. Reading up on what the experts think - and examining whether they believe a share is a 'buy', 'hold' or 'sell' - can be very useful. For investors, thes...
Company analysts usually understand the stocks they cover better than just about anyone else. For that reason, it can be useful to know whether they think investors should 'buy', 'hold' or 'sell' them. These kinds of clues can give you...
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Latest News for CLIN
Upcoming Events for CLIN
Half Year 2022 Clinigen Group PLC Earnings Release
As of Today at 07:18 UTC, shares in Clinigen are trading at 782.50p. This share price information is delayed by 15 minutes.
Shares in Clinigen last closed at 782.50p and the price had moved by +22.17% over the past 365 days. In terms of relative price strength the Clinigen share price has outperformed the FTSE All Share Index by +11.23% over the past year.
The overall consensus recommendation for Clinigen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Clinigen dividend yield is 0.97% based on the trailing twelve month period.
Last year, Clinigen paid a total dividend of £0.08, and it currently has a trailing dividend yield of 0.97%.Looking ahead, the next dividend pay date is 2022-01-04.
We do not have data on when Clinigen is to next pay dividends. The historic dividend yield on Clinigen shares is currently 0.97%.
To buy shares in Clinigen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 782.50p, shares in Clinigen had a market capitalisation of £1.73bn.
Here are the trading details for Clinigen:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: CLIN
Based on an overall assessment of its quality, value and momentum Clinigen is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Clinigen is 762.26p. That is 2.59% below the last closing price of 782.50p.
Analysts covering Clinigen currently have a consensus Earnings Per Share (EPS) forecast of £0.55 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clinigen. Over the past six months, its share price has outperformed the FTSE All Share Index by +26.76%.
As of the last closing price of 782.50p, shares in Clinigen were trading +13.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Clinigen PE ratio based on its reported earnings over the past 12 months is 13.51. The shares last closed at 782.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Clinigen's management team is headed by:
- Elmar Schnee - NEC
- Shaun Chilton - CEO
- Richard Paling - CFO
- Sam Herbert - COO
- Amanda Miller - GCN
- Alan Boyd - NED
- Sharon Curran - NID
- Anne Hyland - NID
- Ian Johnson - NID
- Ian Nicholson - NID